Charles Rudin - Publications

Affiliations: 
University of Chicago, Chicago, IL 
Area:
Molecular Biology

171 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Manoj P, Donoghue MTA, Won HH, Chan JM, Ciampricotti M, Chow A, Offin M, Chang JC, ... ... Rudin CM, et al. Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discovery. PMID 34155000 DOI: 10.1158/2159-8290.CD-20-1863  0.52
2021 Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, Poirier JT, Peng D, Bulatovic M, Mukhopadhyay S, Silver H, Papadopoulos E, Pyon V, Thakurdin C, Han H, ... ... Rudin CM, et al. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. Nature Cancer. 2: 503-514. PMID 34142094 DOI: 10.1038/s43018-021-00208-6  0.52
2021 Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, ... ... Rudin CM, et al. Tim-4 cavity-resident macrophages impair anti-tumor CD8 T cell immunity. Cancer Cell. PMID 34115989 DOI: 10.1016/j.ccell.2021.05.006  0.52
2021 Jayawardena N, Miles LA, Burga LN, Rudin C, Wolf M, Poirier JT, Bostina M. N-Linked Glycosylation on Anthrax Toxin Receptor 1 Is Essential for Seneca Valley Virus Infection. Viruses. 13. PMID 33924774 DOI: 10.3390/v13050769  0.52
2021 Sharma SK, Adumeau P, Keinänen O, Sisodiya V, Sarvaiya H, Tchelepi R, Korsen JA, Pourat J, Edwards KJ, Ragupathi A, Hamdy O, Saunders LR, Rudin CM, Poirier JT, Lewis JS, et al. Synthesis and Comparative Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. Bioconjugate Chemistry. PMID 33835770 DOI: 10.1021/acs.bioconjchem.1c00121  0.52
2021 Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, Karajannis MA, Hanemann CO, Giancotti FG. Correction: Combined Inhibition of NEDD8-activating Enzyme and mTOR Suppresses NF2 Loss-driven Tumorigenesis. Molecular Cancer Therapeutics. 20: 450. PMID 33547247 DOI: 10.1158/1535-7163.MCT-20-1027  0.52
2020 Hulton CH, Costa EA, Shah NS, Quintanal-Villalonga A, Heller G, de Stanchina E, Rudin CM, Poirier JT. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid functional genomics. Nature Cancer. 1: 359-369. PMID 33345196 DOI: 10.1038/s43018-020-0040-8  0.52
2020 Hoffmann HH, Schneider WM, Rozen-Gagnon K, Miles LA, Schuster F, Razooky B, Jacobson E, Wu X, Yi S, Rudin CM, MacDonald MR, McMullan LK, Poirier JT, Rice CM. TMEM41B Is a Pan-flavivirus Host Factor. Cell. PMID 33338421 DOI: 10.1016/j.cell.2020.12.005  0.52
2020 Wohlhieter CA, Richards AL, Uddin F, Hulton CH, Quintanal-Villalonga À, Martin A, de Stanchina E, Bhanot U, Asher M, Shah NS, Hayatt O, Buonocore DJ, Rekhtman N, Shen R, Arbour KC, ... ... Rudin CM, et al. Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell Reports. 33: 108444. PMID 33264619 DOI: 10.1016/j.celrep.2020.108444  0.52
2020 Hoffmann HH, Schneider WM, Rozen-Gagnon K, Miles LA, Schuster F, Razooky B, Jacobson E, Wu X, Yi S, Rudin CM, MacDonald MR, McMullan LK, Poirier JT, Rice CM. TMEM41B is a pan-flavivirus host factor. Biorxiv : the Preprint Server For Biology. PMID 33052348 DOI: 10.1101/2020.10.09.334128  0.52
2020 Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth A, Daneshbod Y, Beras A, Spencer R, Lopardo J, Bodd F, Montecalvo J, Sauter JL, Chang JC, Buonocore DJ, Travis WD, ... ... Rudin CM, et al. Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33011388 DOI: 10.1016/j.jtho.2020.09.009  0.52
2020 Marjanovic ND, Hofree M, Chan JE, Canner D, Wu K, Trakala M, Hartmann GG, Smith OC, Kim JY, Evans KV, Hudson A, Ashenberg O, Porter CBM, Bejnood A, Subramanian A, ... ... Rudin CM, et al. Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell. PMID 32707077 DOI: 10.1016/J.Ccell.2020.06.012  0.52
2020 Kern JA, Kim J, Foster DG, Mishra R, Gardner EE, Poirier JT, Rivard C, Yu H, Finigan JH, Dowlati A, Rudin CM, Tan AC. Role of mTOR as an essential kinase in SCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32599072 DOI: 10.1016/J.Jtho.2020.05.026  0.52
2020 Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, ... ... Rudin CM, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discovery. PMID 32213539 DOI: 10.1158/2159-8290.Cd-20-0215  0.52
2020 Laughney AM, Hu J, Campbell NR, Bakhoum SF, Setty M, Lavallée VP, Xie Y, Masilionis I, Carr AJ, Kottapalli S, Allaj V, Mattar M, Rekhtman N, Xavier JB, Mazutis L, ... ... Rudin CM, et al. Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nature Medicine. PMID 32042191 DOI: 10.1038/S41591-019-0750-6  0.52
2020 Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, ... ... Rudin CM, et al. New approaches to small cell lung cancer therapy : from the laboratory to the clinic. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32018053 DOI: 10.1016/J.Jtho.2020.01.016  0.52
2019 Rodrigues G, Hoshino A, Kenific CM, Matei IR, Steiner L, Freitas D, Kim HS, Oxley PR, Scandariato I, Casanova-Salas I, Dai J, Badwe CR, Gril B, Tešić Mark M, Dill BD, ... ... Rudin CM, et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nature Cell Biology. PMID 31685984 DOI: 10.1038/S41556-019-0404-4  0.36
2019 Lok BH, Rudin CM. Epigenetic targeting of DNA repair in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 116: 22429-22431. PMID 31662477 DOI: 10.1073/pnas.1916581116  0.36
2019 Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, et al. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31506387 DOI: 10.1158/1078-0432.CCR-19-1133  0.4
2019 Devarakonda S, Sankararaman S, Herzog B, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D. Circulating Tumor DNA Profiling in Small Cell Lung Cancer Identifies Potentially Targetable Alterations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31300452 DOI: 10.1158/1078-0432.Ccr-19-0879  0.52
2019 Laird J, Lok BH, Carney B, Kossatz S, de Stanchina E, Reiner T, Poirier JT, Rudin CM. PET Imaging of a [F]-radiolabeled PARP Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in Small Cell Lung Cancer Patient-Derived Xenografts. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31195178 DOI: 10.1016/J.Jtho.2019.05.032  0.52
2019 Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, et al. Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews. Cancer. PMID 31175338 DOI: 10.1038/S41568-019-0164-2  0.52
2019 Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews. Cancer. PMID 30926931 DOI: 10.1038/S41568-019-0133-9  0.52
2019 Rekhtman N, Desmeules P, Litvak AM, Pietanza MC, Santos-Zabala ML, Ni A, Montecalvo J, Chang JC, Beras A, Preeshagul IR, Sabari JK, Rudin CM, Ladanyi M, Klimstra DS, Travis WD, et al. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 30923345 DOI: 10.1038/s41379-019-0248-2  0.36
2019 Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, et al. Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30831205 DOI: 10.1016/J.Jtho.2018.12.038  0.52
2019 Augert A, Eastwood E, Ibrahim AH, Wu N, Grunblatt E, Basom R, Liggitt D, Eaton KD, Martins R, Poirier JT, Rudin CM, Milletti F, Cheng WY, Mack F, MacPherson D. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Science Signaling. 12. PMID 30723171 DOI: 10.1126/Scisignal.Aau2922  0.52
2019 Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakis N, Drilon A, Rudin CM, et al. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. European Journal of Cancer (Oxford, England : 1990). 109: 28-35. PMID 30685684 DOI: 10.1016/j.ejca.2018.11.030  0.36
2019 Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, ... ... Rudin CM, et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications. 10: 278. PMID 30655535 DOI: 10.1038/S41467-018-08133-6  0.52
2018 Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, ... Rudin CM, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science (New York, N.Y.). 362: 1416-1422. PMID 30573629 DOI: 10.1126/Science.Aas9090  0.52
2018 Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, ... ... Rudin CM, et al. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute. PMID 30496436 DOI: 10.1093/jnci/djy156  0.36
2018 Kumar D, Lisok A, Dahmane E, McCoy MD, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, et al. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. The Journal of Clinical Investigation. PMID 30457978 DOI: 10.1172/Jci122216  0.52
2018 Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, et al. Activation of KRAS mediates resistance to targeted therapy in MET ex on 14 mutant non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30352902 DOI: 10.1158/1078-0432.CCR-18-1640  0.36
2018 Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin MD, Arbour KC, Plodkowski AJ, Halpenny DF, ... ... Rudin CM, et al. PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30165371 DOI: 10.1093/Annonc/Mdy334  0.36
2018 Laird JH, Lok BH, Ma J, Bell A, de Stanchina E, Poirier JT, Rudin CM. Talazoparib is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29945991 DOI: 10.1158/1078-0432.Ccr-18-0401  0.52
2018 Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, ... ... Rudin CM, et al. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018777672. PMID 29906251 DOI: 10.1200/Jco.2018.77.7672  0.4
2018 Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty NVK, Weber WA, Rudin CM, Poirier JT, Reiner T. Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nature Communications. 9: 176. PMID 29330466 DOI: 10.1038/S41467-017-02096-W  0.52
2017 Lok BH, Ma J, Foster A, Perez CA, Shi W, Zhang Z, Li BT, Rudin CM, Rimner A, Wu AJ. Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Advances in Radiation Oncology. 2: 548-554. PMID 29204521 DOI: 10.1016/j.adro.2017.08.001  0.36
2017 Miles LA, Burga LN, Gardner EE, Bostina M, Poirier JT, Rudin CM. Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. The Journal of Clinical Investigation. PMID 28650343 DOI: 10.1172/Jci93472  0.52
2017 Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nature Reviews. Clinical Oncology. PMID 28534531 DOI: 10.1038/Nrclinonc.2017.71  0.52
2017 Sharma SK, Pourat J, Abdel-Atti D, Carlin SD, Piersigilli A, Bankovich AJ, Gardner EE, Hamdy O, Isse K, Bheddah S, Sandoval J, Cunanan KM, Johansen EB, Allaj V, Sisodiya V, ... ... Rudin CM, et al. Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Research. PMID 28487384 DOI: 10.1158/0008-5472.Can-17-0299  0.52
2017 Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, Karajannis MA, Hanemann CO, Giancotti FG. Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. Molecular Cancer Therapeutics. PMID 28468780 DOI: 10.1158/1535-7163.Mct-16-0821  0.52
2017 Gardner EE, Poirier JT, Rudin CM. Histone Code Aberrancies in Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 12: 599-601. PMID 28343540 DOI: 10.1016/J.Jtho.2017.02.008  0.52
2017 Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, ... ... Rudin CM, et al. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer Cell. 31: 286-299. PMID 28196596 DOI: 10.1016/J.Ccell.2017.01.006  0.52
2016 Rudin CM, Poirier JT. Small-cell lung cancer in 2016: Shining light on novel targets and therapies. Nature Reviews. Clinical Oncology. PMID 27958293 DOI: 10.1038/Nrclinonc.2016.203  0.52
2016 Lok BH, Feng Y, Gardner EE, Yu GK, Ru YK, Riaz N, deStanchina E, Powell SN, Shen YJ, Poirier JT, Rudin CM. SLFN11 Is Necessary for Single Agent Sensitivity to Talazoparib, a Potent PARP Inhibitor, But Not for Radiosensitization in Small Cell Lung Cancer (SCLC) Cell Lines and Patient-Derived Xenografts (PDX). International Journal of Radiation Oncology, Biology, Physics. 96: S75. PMID 27676009 DOI: 10.1016/J.Ijrobp.2016.06.191  0.52
2016 Schneeberger VE, Allaj V, Gardner EE, Poirier JT, Rudin CM. Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis. Plos One. 11: e0160587. PMID 27611664 DOI: 10.1371/Journal.Pone.0160587  0.52
2016 Pietanza MC, Litvak AM, Varghese AM, Krug LM, Fleisher M, Teitcher JB, Holodny AI, Sima CS, Woo KM, Ng KK, Won HH, Berger MF, Kris MG, Rudin CM. A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 99: 23-30. PMID 27565909 DOI: 10.1016/j.lungcan.2016.04.014  0.96
2016 Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, Poirier JT, Rudin CM. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27440269 DOI: 10.1158/1078-0432.Ccr-16-1040  0.52
2016 Shamay Y, Elkabets M, Li H, Shah J, Brook S, Wang F, Adler K, Baut E, Scaltriti M, Jena PV, Gardner EE, Poirier JT, Rudin CM, Baselga J, Haimovitz-Friedman A, et al. P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Science Translational Medicine. 8: 345ra87. PMID 27358497 DOI: 10.1126/Scitranslmed.Aaf7374  0.96
2016 Manchado E, Weissmueller S, Morris JP, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. PMID 27338794 DOI: 10.1038/Nature18600  0.52
2016 Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, ... ... Rudin CM, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. The Journal of Clinical Investigation. PMID 27294525 DOI: 10.1172/Jci81603  0.96
2016 Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. PMID 27163943 DOI: 10.1002/cncr.30062  0.96
2016 Rekhtman N, Pietanza MC, Hellmann M, Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, Paik PK, Drilon A, Socci N, Poirier JT, Shen R, ... ... Rudin CM, et al. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26960398 DOI: 10.1158/1078-0432.Ccr-15-2946  0.96
2016 Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, Kris MG, Riely GJ, Lito P, Iqbal A, Veach S, Smith-Marrone S, Sarkaria IS, Krug LM, Rudin CM, et al. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer. PMID 26898325 DOI: 10.1016/J.Cllc.2016.01.003  0.96
2016 Bunn PA, Minna J, Augustyn A, Gazdar A, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier J, ... ... Rudin CM, et al. Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes? Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26829312 DOI: 10.1016/J.Jtho.2016.01.012  0.96
2015 Zong H, Gozman A, Caldas-Lopes E, Taldone T, Sturgill E, Brennan S, Ochiana SO, Gomes-DaGama EM, Sen S, Rodina A, Koren J, Becker MW, Rudin CM, Melnick A, Levine RL, et al. A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell Reports. PMID 26628369 DOI: 10.1016/J.Celrep.2015.10.073  0.96
2015 Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, ... ... Rudin CM, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine. 373: 1627-39. PMID 26412456 DOI: 10.1056/NEJMoa1507643  0.96
2015 Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, Pietanza MC, Ramalingam SS, Turrisi AT, Giaccone G. Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26351333 DOI: 10.1200/JCO.2015.63.7918  0.4
2015 Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, ... ... Rudin CM, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Science Translational Medicine. 7: 302ra136. PMID 26311731 DOI: 10.1126/Scitranslmed.Aac9459  0.96
2015 Miles LA, Brennen WN, Rudin CM, Poirier JT. Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy. Plos One. 10: e0136480. PMID 26287921 DOI: 10.1371/Journal.Pone.0136480  0.52
2015 Ujiie H, Kadota K, Chaft JE, Buitrago D, Sima CS, Lee MC, Huang J, Travis WD, Rizk NP, Rudin CM, Jones DR, Adusumilli PS. Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26261257 DOI: 10.1200/JCO.2015.60.9818  0.96
2015 Miles LA, Brennen WN, Rudin CM, Poirier JT. Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy. Plos One. 10: e0129103. PMID 26069962 DOI: 10.1371/journal.pone.0129103  0.96
2015 Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. Journal of the American Academy of Dermatology. 72: 1021-6.e8. PMID 25981002 DOI: 10.1016/J.Jaad.2015.03.021  0.96
2015 Pietanza MC, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2244-55. PMID 25979931 DOI: 10.1158/1078-0432.CCR-14-2958  0.96
2015 Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, Ladanyi M. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discovery. PMID 25971939 DOI: 10.1158/2159-8290.CD-14-1467  0.96
2015 Chandra V, Das T, Gulati P, Biswas NK, Rote S, Chatterjee U, Ghosh SN, Deb S, Saha SK, Chowdhury AK, Ghosh S, Rudin CM, Mukherjee A, Basu A, Dhara S. Hedgehog signaling pathway is active in GBM with GLI1 mRNA expression showing a single continuous distribution rather than discrete high/low clusters. Plos One. 10: e0116390. PMID 25775002 DOI: 10.1371/journal.pone.0116390  0.96
2015 Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, ... Rudin CM, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 27: 327-41. PMID 25759019 DOI: 10.1016/J.Ccell.2015.02.001  0.96
2015 Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, ... ... Rudin CM, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications. 6: 6377. PMID 25758528 DOI: 10.1038/Ncomms7377  0.96
2015 Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, Rudin CM. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene. PMID 25746006 DOI: 10.1038/Onc.2015.38  0.96
2015 Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, ... ... Rudin CM, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature Genetics. 47: 250-6. PMID 25665005 DOI: 10.1038/Ng.3218  0.96
2015 Jimeno A, Bauman JE, Weissman C, Adkins D, Schnadig I, Beauregard P, Bowles DW, Spira A, Levy B, Seetharamu N, Hausman D, Walker L, Rudin CM, Shirai K. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncology. 51: 383-8. PMID 25593016 DOI: 10.1016/j.oraloncology.2014.12.013  0.96
2015 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: S1-63. PMID 25535693 DOI: 10.1097/Jto.0000000000000405  0.96
2015 Vendetti FP, Topper M, Huang P, Dobromilskaya I, Easwaran H, Wrangle J, Baylin SB, Poirier JT, Rudin CM. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget. 6: 56-70. PMID 25474141 DOI: 10.18632/Oncotarget.2695  0.96
2015 Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 121: 664-72. PMID 25336398 DOI: 10.1002/cncr.29098  0.96
2015 Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatric Blood & Cancer. 62: 743-50. PMID 25307519 DOI: 10.1002/Pbc.25269  0.96
2015 Bai RY, Staedtke V, Rudin CM, Bunz F, Riggins GJ. Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro-Oncology. 17: 545-54. PMID 25253417 DOI: 10.1093/neuonc/nou234  0.96
2014 Litvak AM, Paik PK, Woo KM, Sima CS, Hellmann MD, Arcila ME, Ladanyi M, Rudin CM, Kris MG, Riely GJ. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1669-74. PMID 25436800 DOI: 10.1097/JTO.0000000000000344  0.96
2014 Drilon A, Sugita H, Sima CS, Zauderer M, Rudin CM, Kris MG, Rusch VW, Azzoli CG. A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1272-7. PMID 25122424 DOI: 10.1097/JTO.0000000000000256  0.96
2014 Rudin CM, Drilon A, Poirier JT. RET mutations in neuroendocrine tumors: including small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1240-2. PMID 25122419 DOI: 10.1097/Jto.0000000000000301  0.96
2014 Levy B, Spira A, Becker D, Evans T, Schnadig I, Camidge DR, Bauman JE, Hausman D, Walker L, Nemunaitis J, Rudin CM, Halmos B, Bowles DW. A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1031-5. PMID 24926548 DOI: 10.1097/JTO.0000000000000183  0.96
2014 Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, ... ... Rudin C, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama. 311: 1998-2006. PMID 24846037 DOI: 10.1001/Jama.2014.3741  0.96
2014 Dogan I, Kawabata S, Bergbower E, Gills JJ, Ekmekci A, Wilson W, Rudin CM, Dennis PA. SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. Lung Cancer (Amsterdam, Netherlands). 85: 1-6. PMID 24746758 DOI: 10.1016/j.lungcan.2014.03.021  0.96
2014 Gardner EE, Connis N, Poirier JT, Cope L, Dobromilskaya I, Gallia GL, Rudin CM, Hann CL. Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Research. 74: 2846-56. PMID 24614082 DOI: 10.1158/0008-5472.Can-13-3460  0.96
2014 Rudin CM, Poirier JT. MYC, MAX, and small cell lung cancer. Cancer Discovery. 4: 273-4. PMID 24596200 DOI: 10.1158/2159-8290.Cd-14-0069  0.96
2014 Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: E748-57. PMID 24550319 DOI: 10.1073/Pnas.1320956111  0.96
2014 Forde PM, Hooker CM, Boikos SA, Petrini I, Giaccone G, Rudin CM, Yang SC, Illei PB, Hann CL, Ettinger DS, Brahmer JR, Kelly RJ. Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 414-8. PMID 24518093 DOI: 10.1097/JTO.0000000000000065  0.96
2014 Kanarek NF, Hooker CM, Mathieu L, Tsai HL, Rudin CM, Herman JG, Brock MV. Survival after community diagnosis of early-stage non-small cell lung cancer. The American Journal of Medicine. 127: 443-9. PMID 24486286 DOI: 10.1016/j.amjmed.2013.12.023  0.96
2014 Mathieu LN, Kanarek NF, Tsai HL, Rudin CM, Brock MV. Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008). Diseases of the Esophagus : Official Journal of the International Society For Diseases of the Esophagus / I.S.D.E. 27: 757-63. PMID 24118313 DOI: 10.1111/dote.12147  0.96
2013 Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, ... ... Rudin CM, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 4: 2067-79. PMID 24162015 DOI: 10.18632/Oncotarget.1542  0.96
2013 Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F, Ma J, Salih T, Cades J, Fertig E, Biswal S, ... ... Rudin CM, et al. The twist box domain is required for Twist1-induced prostate cancer metastasis. Molecular Cancer Research : McR. 11: 1387-400. PMID 23982216 DOI: 10.1158/1541-7786.Mcr-13-0218-T  0.96
2013 Bowles DW, Ma WW, Senzer N, Brahmer JR, Adjei AA, Davies M, Lazar AJ, Vo A, Peterson S, Walker L, Hausman D, Rudin CM, Jimeno A. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. British Journal of Cancer. 109: 1085-92. PMID 23942080 DOI: 10.1038/bjc.2013.474  0.96
2013 Vendetti FP, Rudin CM. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert Opinion On Biological Therapy. 13: 1273-85. PMID 23859704 DOI: 10.1517/14712598.2013.819337  0.96
2013 Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. Journal of the National Cancer Institute. 105: 1059-65. PMID 23739064 DOI: 10.1093/Jnci/Djt130  0.96
2013 Juergens RA, Rudin CM. Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic target. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. PMID 23714528 DOI: 10.1200/EdBook_AM.2013.33.e295  0.96
2013 Jimeno A, Weiss GJ, Miller WH, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, ... Rudin CM, et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2766-74. PMID 23575478 DOI: 10.1158/1078-0432.Ccr-12-3654  0.96
2013 Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours--lessons from the past. Nature Reviews. Clinical Oncology. 10: 256-66. PMID 23546521 DOI: 10.1038/Nrclinonc.2013.42  0.96
2013 Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P, Liu JO. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 619-23. PMID 23546045 DOI: 10.1097/Jto.0B013E31828C3950  0.96
2013 Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: e41-2. PMID 23524406 DOI: 10.1097/JTO.0b013e31828bb1b3  0.96
2013 Zinn RL, Gardner EE, Marchionni L, Murphy SC, Dobromilskaya I, Hann CL, Rudin CM. ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer. Molecular Cancer Therapeutics. 12: 1131-9. PMID 23515613 DOI: 10.1158/1535-7163.MCT-12-0618  0.96
2013 Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2584-91. PMID 23515407 DOI: 10.1158/1078-0432.Ccr-12-3173  0.96
2013 Zinn RL, Gardner EE, Dobromilskaya I, Murphy S, Marchionni L, Hann CL, Rudin CM. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. Molecular Cancer. 12: 16. PMID 23452820 DOI: 10.1186/1476-4598-12-16  0.96
2013 Kamat CD, Shmueli RB, Connis N, Rudin CM, Green JJ, Hann CL. Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo. Molecular Cancer Therapeutics. 12: 405-15. PMID 23364678 DOI: 10.1158/1535-7163.MCT-12-0956  0.96
2013 Burns TF, Dobromilskaya I, Murphy SC, Gajula RP, Thiyagarajan S, Chatley SN, Aziz K, Cho YJ, Tran PT, Rudin CM. Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer. Molecular Cancer Research : McR. 11: 329-38. PMID 23364532 DOI: 10.1158/1541-7786.MCR-12-0456  0.96
2013 Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, ... ... Rudin CM, et al. Small cell lung cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 78-98. PMID 23307984  0.96
2013 Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, Riggins GJ, Epstein EH, Beachy PA, Rudin CM. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 23: 23-34. PMID 23291299 DOI: 10.1016/J.Ccr.2012.11.017  0.96
2013 Zeng J, Aziz K, Chettiar ST, Aftab BT, Armour M, Gajula R, Gandhi N, Salih T, Herman JM, Wong J, Rudin CM, Tran PT, Hales RK. Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers. International Journal of Radiation Oncology, Biology, Physics. 86: 143-9. PMID 23182391 DOI: 10.1016/j.ijrobp.2012.10.014  0.96
2012 Poirier JT, Reddy PS, Idamakanti N, Li SS, Stump KL, Burroughs KD, Hallenbeck PL, Rudin CM. Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001. The Journal of General Virology. 93: 2606-13. PMID 22971818 DOI: 10.1099/Vir.0.046011-0  0.96
2012 Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature Genetics. 44: 1111-6. PMID 22941189 DOI: 10.1038/Ng.2405  0.96
2012 Rudin CM. Vismodegib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3218-22. PMID 22679179 DOI: 10.1158/1078-0432.CCR-12-0568  0.96
2012 Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. The New England Journal of Medicine. 366: 2171-9. PMID 22670903 DOI: 10.1056/Nejmoa1113713  0.96
2012 Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, Chen J, Cho YJ, Luong R, Tamayo P, Salih T, Aziz K, Adam SJ, Vicent S, Nielsen CH, ... ... Rudin CM, et al. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. Plos Genetics. 8: e1002650. PMID 22654667 DOI: 10.1371/Journal.Pgen.1002650  0.96
2012 Forde PM, Rudin CM. Crizotinib in the treatment of non-small-cell lung cancer. Expert Opinion On Pharmacotherapy. 13: 1195-201. PMID 22594847 DOI: 10.1517/14656566.2012.688029  0.96
2012 Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3163-9. PMID 22496272 DOI: 10.1158/1078-0432.CCR-11-3090  0.96
2012 Pietanza MC, Rudin CM. Novel therapeutic approaches for small cell lung cancer: the future has arrived. Current Problems in Cancer. 36: 156-73. PMID 22495056 DOI: 10.1016/j.currproblcancer.2012.03.005  0.96
2012 Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, Olsson A, Ahrens W, Gross IM, Brüske I, Wichmann HE, Merletti F, Richiardi L, Simonato L, Fortes C, ... ... Rudin CM, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. International Journal of Cancer. Journal International Du Cancer. 131: 1210-9. PMID 22052329 DOI: 10.1002/Ijc.27339  0.96
2012 Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, Hong SM, Zhao M, Rudek MA, Khan SR, Rudin CM, Maitra A. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Molecular Cancer Therapeutics. 11: 165-73. PMID 22027695 DOI: 10.1158/1535-7163.Mct-11-0341  0.96
2011 Burns TF, Dobromilskaya I, Murphy S, Thiyagarajan S, Das S, Tran PT, Rudin CM. Reactivation of oncogene-induced senescence in KRAS mutant non-small cell lung cancer by inhibition of TWIST1. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10591. PMID 28021973 DOI: 10.1200/jco.2011.29.15_suppl.10591  0.4
2011 Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, ... ... Rudin CM, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discovery. 1: 598-607. PMID 22586682 DOI: 10.1158/2159-8290.Cd-11-0214  0.96
2011 Osanyingbemi-Obidi J, Dobromilskaya I, Illei PB, Hann CL, Rudin CM. Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Molecular Cancer Research : McR. 9: 1746-54. PMID 21994468 DOI: 10.1158/1541-7786.MCR-11-0286  0.96
2011 Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, ... ... Rudin CM, et al. Small cell lung cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 1086-113. PMID 21975911  0.96
2011 Shi W, Nacev BA, Aftab BT, Head S, Rudin CM, Liu JO. Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling. Journal of Medicinal Chemistry. 54: 7363-74. PMID 21936514 DOI: 10.1021/Jm200944B  0.96
2011 Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, Murphy SC, Erlichman C, Rudin CM, Govindan R. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1757-60. PMID 21918390 DOI: 10.1097/JTO.0b013e31822e2941  0.96
2011 Aftab BT, Dobromilskaya I, Liu JO, Rudin CM. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Research. 71: 6764-72. PMID 21896639 DOI: 10.1158/0008-5472.Can-11-0691  0.96
2011 Husain H, Rudin CM. ALK-targeted therapy for lung cancer: ready for prime time. Oncology (Williston Park, N.Y.). 25: 597-601. PMID 21888258  0.96
2011 Zhang YA, Maitra A, Hsieh JT, Rudin CM, Peacock CD, Karikari C, Brekken RA, Stastny V, Gao B, Girard L, Wistuba I, Frenkel E, Minna JD, Gazdar AF. Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biology & Therapy. 12: 617-28. PMID 21750403 DOI: 10.4161/Cbt.12.7.15955  0.96
2011 Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 74: 481-5. PMID 21620511 DOI: 10.1016/J.Lungcan.2011.05.005  0.96
2011 Rudin CM, Poirier JT, Senzer NN, Stephenson J, Loesch D, Burroughs KD, Reddy PS, Hann CL, Hallenbeck PL. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 888-95. PMID 21304001 DOI: 10.1158/1078-0432.Ccr-10-1706  0.96
2011 Rudin CM, Mauer A, Smakal M, Juergens R, Spelda S, Wertheim M, Coates A, McKeegan E, Ansell P, Zhou X, Qian J, Pradhan R, Dowell B, Krivoshik A, Gordon G. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1075-82. PMID 21300929 DOI: 10.1200/Jco.2010.32.5944  0.96
2011 LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2502-11. PMID 21300762 DOI: 10.1158/1078-0432.Ccr-10-2745  0.96
2011 Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, Rudin CM, Reddy JC, Low JA, Lorusso PM. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2512-20. PMID 21300760 DOI: 10.1158/1078-0432.Ccr-10-2736  0.96
2011 Kaneko H, Dridi S, Tarallo V, Gelfand BD, Fowler BJ, Cho WG, Kleinman ME, Ponicsan SL, Hauswirth WW, Chiodo VA, Karikó K, Yoo JW, Lee DK, Hadziahmetovic M, Song Y, ... ... Rudin CM, et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature. 471: 325-30. PMID 21297615 DOI: 10.1038/Nature09830  0.96
2011 Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, ... ... Rudin CM, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 909-16. PMID 21282543 DOI: 10.1200/JCO.2010.31.6208  0.96
2010 Klamerus JF, Bruinooge SS, Ye X, Klamerus ML, Damron D, Lansey D, Lowery JC, Diaz LA, Ford JG, Kanarek N, Rudin CM. The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5997-6003. PMID 21169253 DOI: 10.1158/1078-0432.CCR-10-1451  0.96
2010 Kanarek NF, Tsai HL, Metzger-Gaud S, Damron D, Guseynova A, Klamerus JF, Rudin CM. Geographic proximity and racial disparities in cancer clinical trial participation. Journal of the National Comprehensive Cancer Network : Jnccn. 8: 1343-51. PMID 21147901  0.96
2010 Peacock CD, Rudin CM. Skin deep and deeper: multiple pathways in basal cell carcinogenesis. Cancer Prevention Research (Philadelphia, Pa.). 3: 1213-6. PMID 20858762 DOI: 10.1158/1940-6207.CAPR-10-0203  0.96
2009 Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, Schwartz AG, Vahakangas KH, Samet JM. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5646-61. PMID 19755392 DOI: 10.1158/1078-0432.Ccr-09-0377  0.96
2009 Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, ... ... Rudin CM, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (New York, N.Y.). 326: 572-4. PMID 19726788 DOI: 10.1126/science.1179386  0.96
2009 Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC, de Sauvage FJ, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. The New England Journal of Medicine. 361: 1164-72. PMID 19726763 DOI: 10.1056/NEJMoa0905360  0.96
2009 Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD, Watkins DN. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Research. 69: 3364-73. PMID 19351829 DOI: 10.1158/0008-5472.CAN-08-4210  0.96
2009 Guarino MJ, Schneider CJ, Hosford MA, Brahmer JR, Rudin CM, Finckenstein FG, Philip-Norton RE, Lu H, Weber MR, Ettinger DS. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. The Oncologist. 14: 119-24. PMID 19182243 DOI: 10.1634/theoncologist.2008-0124  0.96
2009 Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM, Seshan VE, Fogle M, Ginsberg M, Miller VA, Rudin CM. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 264-70. PMID 19047285 DOI: 10.1200/Jco.2008.17.4656  0.96
2009 Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, Evans WE, Pieters R, Den Boer ML. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 113: 2014-21. PMID 18978206 DOI: 10.1182/Blood-2008-05-157842  0.96
2008 Rudin CM, Hann CL, Peacock CD, Watkins DN. Novel systemic therapies for small cell lung cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 6: 315-22. PMID 18377849 DOI: 10.6004/JNCCN.2008.0026  0.4
2007 Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele KL, Vasko AJ, Yang J, Watkins DN, Rudin CM, Hallenbeck PL. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. Journal of the National Cancer Institute. 99: 1623-33. PMID 17971529 DOI: 10.1093/jnci/djm198  0.96
2007 Hann CL, Rudin CM. Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends in Molecular Medicine. 13: 150-7. PMID 17324626 DOI: 10.1016/j.molmed.2007.02.003  0.4
2007 Hagan CR, Rudin CM. DNA cleavage and Trp53 differentially affect SINE transcription. Genes, Chromosomes & Cancer. 46: 248-60. PMID 17171681 DOI: 10.1002/Gcc.20406  1
2007 Brace JL, Lester RL, Dickson RC, Rudin CM. SVF1 regulates cell survival by affecting sphingolipid metabolism in Saccharomyces cerevisiae. Genetics. 175: 65-76. PMID 17057230 DOI: 10.1534/genetics.106.064527  0.8
2006 Ross HJ, Hart LL, Swanson PM, Rarick MU, Figlin RA, Jacobs AD, McCune DE, Rosenberg AH, Baron AD, Grove LE, Thorn MD, Miller DM, Drachman JG, Rudin CM. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer (Amsterdam, Netherlands). 54: 69-77. PMID 16934909 DOI: 10.1016/j.lungcan.2006.05.020  0.96
2005 Vanderweele DJ, Rudin CM. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate. Molecular Cancer Research : McR. 3: 635-44. PMID 16317089 DOI: 10.1158/1541-7786.Mcr-05-0063  0.96
2005 Brace JL, Vanderweele DJ, Rudin CM. Svf1 inhibits reactive oxygen species generation and promotes survival under conditions of oxidative stress in Saccharomyces cerevisiae. Yeast (Chichester, England). 22: 641-52. PMID 16034825 DOI: 10.1002/Yea.1235  0.96
2005 Brock MV, Hooker CM, Syphard JE, Westra W, Xu L, Alberg AJ, Mason D, Baylin SB, Herman JG, Yung RC, Brahmer J, Rudin CM, Ettinger DS, Yang SC. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. The Journal of Thoracic and Cardiovascular Surgery. 129: 64-72. PMID 15632826 DOI: 10.1016/J.Jtcvs.2004.08.022  0.96
2004 VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Molecular Cancer Therapeutics. 3: 1605-13. PMID 15634654  0.96
2004 Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Research. 64: 3892-9. PMID 15172999 DOI: 10.1158/0008-5472.Can-03-2904  0.96
2003 Hagan CR, Sheffield RF, Rudin CM. Human Alu element retrotransposition induced by genotoxic stress. Nature Genetics. 35: 219-20. PMID 14578886 DOI: 10.1038/Ng1259  0.96
2003 Carthy CM, Yanagawa B, Luo H, Granville DJ, Yang D, Cheung P, Cheung C, Esfandiarei M, Rudin CM, Thompson CB, Hunt DW, McManus BM. Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection. Virology. 313: 147-57. PMID 12951029 DOI: 10.1016/S0042-6822(03)00242-3  0.96
2003 Karnauskas R, Niu Q, Talapatra S, Plas DR, Greene ME, Crispino JD, Rudin CM. Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo. Oncogene. 22: 688-98. PMID 12569361 DOI: 10.1038/Sj.Onc.1206159  0.96
2003 Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG, Cullen KJ. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Research. 63: 312-8. PMID 12543781  0.96
2002 Vander Heiden MG, Choy JS, VanderWeele DJ, Brace JL, Harris MH, Bauer DE, Prange B, Kron SJ, Thompson CB, Rudin CM. Bcl-x(L) complements Saccharomyces cerevisiae genes that facilitate the switch from glycolytic to oxidative metabolism. The Journal of Biological Chemistry. 277: 44870-6. PMID 12244097 DOI: 10.1074/Jbc.M204888200  0.96
2002 Hagan CR, Rudin CM. Mobile genetic element activation and genotoxic cancer therapy: potential clinical implications. American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice. 2: 25-35. PMID 12083952 DOI: 10.2165/00129785-200202010-00003  1
2002 Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B, George CM, Szeto L, Vokes EE. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 13: 539-45. PMID 12056703 DOI: 10.1093/annonc/mdf124  0.96
2001 George CM, Haraf DJ, Mauer AM, Krauss SA, Hoffman PC, Rudin CM, Szeto L, Vokes EE. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Investigational New Drugs. 19: 303-10. PMID 11561689 DOI: 10.1023/A:1010653508700  0.96
2001 Rudin CM, Thompson CB. Transcriptional activation of short interspersed elements by DNA-damaging agents. Genes, Chromosomes & Cancer. 30: 64-71. PMID 11107177 DOI: 10.1002/1098-2264(2000)9999:9999<::Aid-Gcc1066>3.0.Co;2-F  0.96
2000 Schor NF, Rudin CM, Hartman AR, Thompson CB, Tyurina YY, Kagan VE. Cell line dependence of Bcl-2-induced alteration of glutathione handling. Oncogene. 19: 472-6. PMID 10656697 DOI: 10.1038/sj.onc.1203324  0.96
1999 Thompson CB, Rathmell JC, Frauwirth KA, Lindsten T, Rudin CM, Opferman JT, Ashton-Rickardt PG, Harris MH, Chandel NS, Schumacker PT, Vander Heiden MG. What keeps a resting T cell alive? Cold Spring Harbor Symposia On Quantitative Biology. 64: 383-7. PMID 11232311 DOI: 10.1101/Sqb.1999.64.383  0.96
1999 Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer. 85: 164-70. PMID 9921989 DOI: 10.1002/(SICI)1097-0142(19990101)85:1<164::AID-CNCR23>3.0.CO;2-Q  0.96
1998 Dragovich T, Rudin CM, Thompson CB. Signal transduction pathways that regulate cell survival and cell death. Oncogene. 17: 3207-13. PMID 9916983 DOI: 10.1038/Sj.Onc.1202587  0.96
1997 Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annual Review of Medicine. 48: 267-81. PMID 9046961 DOI: 10.1146/Annurev.Med.48.1.267  0.96
1996 Rudin CM, Van Dongen J, Thompson CB. Apoptotic signaling in lymphocytes. Current Opinion in Hematology. 3: 35-40. PMID 9372049 DOI: 10.1097/00062752-199603010-00006  0.96
1992 Rudin CM, Storb U. Two conserved essential motifs of the murine immunoglobulin lambda enhancers bind B-cell-specific factors. Molecular and Cellular Biology. 12: 309-20. PMID 1729607 DOI: 10.1128/Mcb.12.1.309  1
1990 Hagman J, Rudin CM, Haasch D, Chaplin D, Storb U. A novel enhancer in the immunoglobulin lambda locus is duplicated and functionally independent of NF kappa B. Genes & Development. 4: 978-92. PMID 2116989 DOI: 10.1101/Gad.4.6.978  0.96
1989 Hagman J, Lo D, Doglio LT, Hackett J, Rudin CM, Haasch D, Brinster R, Storb U. Inhibition of immunoglobulin gene rearrangement by the expression of a lambda 2 transgene. The Journal of Experimental Medicine. 169: 1911-29. PMID 2499652 DOI: 10.1084/Jem.169.6.1911  0.96
Show low-probability matches.